相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma
Keith T. Flaherty et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Allosteric and ATP-competitive kinase inhibitors of mTOR for cancer treatment
Carlos Garcia-Echeverria
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Beyond Rapalog Therapy: Preclinical Pharmacology and Antitumor Activity of WYE-125132, an ATP-Competitive and Specific Inhibitor of mTORC1 and mTORC2
Ker Yu et al.
CANCER RESEARCH (2010)
The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma (Publication with Expression of Concern. See vol. 25, pg. 4194, 2019)
Daniel C. Cho et al.
CLINICAL CANCER RESEARCH (2010)
mTOR and cancer: many loops in one pathway
Alejo Efeyan et al.
CURRENT OPINION IN CELL BIOLOGY (2010)
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer
Sebastien Albert et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
P. Cao et al.
BRITISH JOURNAL OF CANCER (2009)
Treatment of Kidney Cancer Insights Provided by the VHL Tumor-Suppressor Protein
William G. Kaelin
CANCER (2009)
mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option
Constantin A. Dasanu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Targeting Melanoma with Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors
Romina Marone et al.
MOLECULAR CANCER RESEARCH (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
The Pharmacology of mTOR Inhibition
David A. Guertin et al.
SCIENCE SIGNALING (2009)
Mechanism of action of rapalogues: the antiangiogenic hypothesis
Sandrine Faivre et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Class 1A PI3K regulates vessel integrity during development and tumorigenesis
Tina L. Yuan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer
William G. Kaelin
NATURE REVIEWS CANCER (2008)
The effects of mTOR-Akt interactions on anti-apoptotic signaling in vascular endothelial cells
Olivier Dormond et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
The phosphoinositide 3-kinase/Akt pathway: A new target in human renal cell carcinoma therapy
Carole Sourbier et al.
CANCER RESEARCH (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
TOR signaling in growth and metabolism
S Wullschleger et al.
CELL (2006)
TOR signaling in growth and metabolism
Stephan Wullschleger et al.
CELL (2006)
Renal-cell carcinoma
HT Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor
S Hara et al.
ANNALS OF ONCOLOGY (2005)
Role of VHL gene mutation in human cancer
WY Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin
CC Hudson et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Role of Akt signaling in vascular homeostasis and angitogenesis
I Shiojima et al.
CIRCULATION RESEARCH (2002)
Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis
M Velickovic et al.
MODERN PATHOLOGY (2002)
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
K Kondo et al.
CANCER CELL (2002)
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
M Guba et al.
NATURE MEDICINE (2002)
分享论文
